Diabetic hypertension and the use of ACE inhibitors
Research type
Research Study
Full title
How safe is the routine use of Angiotensin converting enzyme Inhibitors (ACE-I) in hypertensive type II diabetic patients? Its influence on pre-existing Diabetic hyporeninaemic hypoaldosteronism
IRAS ID
152295
Contact name
Jenny Ireland
Contact email
Sponsor organisation
University of Ulster
Clinicaltrials.gov Identifier
NA, NA
Research summary
The incidence of type II diabetes in the United Kingdom is 90% and almost half of these individuals are reported to have high blood pressure (Patel B & Mehta A., 2013).
Some diabetics with a raised blood pressure can have a rare underlying condition called diabetic hyporeninaemic hypoaldosteronism where; individuals have low blood levels of substances called aldosterone, renin & angiotensin converting enzyme which are essential for maintaining blood pressure.
Angiotensin converting enzyme Inhibitors (ACE-inhibitors) are the most widely prescribed drugs to control high blood pressure in the general population and are known to have adverse effects, particularly in type II diabetic patients with hyporeninaemic hypoaldosteronism. The major side effects include an abnormal rise in blood potassium and reduced blood sodium levels and a further, decline in blood aldosterone & renin levels. This can exhaust the body's blood pressure control system and in some cases with long term use can cause complications.
The main goal of this research is to determine if:
Type II diabetic patients suffering from high blood pressure and a low aldosterone are more likely to have complications from ACE-inhibitor therapy compared to a non-diabetics also on the drug.
Both type II diabetic and non-diabetic individuals with raised blood pressure will be selected in a consultant lead clinic at the Maidstone hospital. Participants will be capable adults =21-75years old, male/ non-pregnant females, of any ethnic origin and taking ACE-I drug/ not taking blood pressure lowering drugs (controls).
A Single random blood sample will be collected from each patient alongside routine blood collections and tested for aldosterone and angiotensin converting enzyme. The duration of the study involving participants is from the time when consent is granted to the point where a blood sample is donated for the research.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
14/LO/1021
Date of REC Opinion
2 Jun 2014
REC opinion
Unfavourable Opinion